PB1906: IS THERE A PLACE FOR IMATINIB IN THE FIRST-LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA CHRONIC PHASE: REAL LIFE DATA FROM UNIVERSITY CENTER AFTER LONG PERIOD OF FOLLOW-UP

por Lekovic, D., Jovanovic, J., Djordjevic, V., Milosevic, V., Bodrozic, J., Bogdanovic, A.
Publicado 2022

The 3′ End Prothrombin Gene Variants in Serbian Patients with Idiopathic Thrombophilia

por Aradjanski, M, Djordjevic, V, Pruner, I, Tomic, B, Gvozdenov, M, Kovac, M, Radojkovic, D
Publicado 2015

Impact of Genetics on Neoadjuvant Therapy with Complete Pathological Response in Metastatic Colorectal Cancer: Case Report and Review of the Literature

por Bulajic, P, Bidzic, N, Djordjevic, V, Ceranic, Μ, Βasaric, D, Pesic, V, Djordjevic-Pesic, J
Publicado 2019

NGS Nominated CELA1, HSPG2, and KCNK5 as Candidate Genes for Predisposition to Balkan Endemic Nephropathy

por Toncheva, D., Mihailova-Hristova, M., Vazharova, R., Staneva, R., Karachanak, S., Dimitrov, P., Simeonov, V., Ivanov, S., Balabanski, L., Serbezov, D., Malinov, M., Stefanovic, V., Čukuranović, R., Polenakovic, M., Jankovic-Velickovic, L., Djordjevic, V., Jevtovic-Stoimenov, T., Plaseska-Karanfilska, D., Galabov, A., Djonov, V., Dimova, I.
Publicado 2014